Bolt Biotherapeutics
BOLT
40 hedge funds and large institutions have $32.1M invested in Bolt Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.
0.23% more ownership
Funds ownership: 3.08% → 3.31% (+0.23%)
0% more funds holding
Funds holding: 40 → 40 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1% less capital invested
Capital invested by funds: $32.4M → $32.1M (-$321K)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.71M |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
+$731K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$277K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$234K |
| 5 |
Squarepoint
New York
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$433K |
| 2 |
Millennium Management
New York
|
-$209K |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$195K |
| 4 |
NM
Newtyn Management
New York
|
-$183K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$107K |
BOLT Hedge Fund Activity: Q2 2023 in Review
40 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2023, worth a combined $32.1M — down 0.99% from $32.4M a quarter earlier.
Fund positioning in BOLT was balanced in Q2 2023: 4 funds opened new positions, 4 closed out, 8 added to existing stakes and 9 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $2.71M. The largest seller was Morgan Stanley, cutting an estimated $433K.
- 40 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $32.1M of Bolt Biotherapeutics stock for Q2 2023, down 0.99% quarter-over-quarter.
- 4 funds opened new Bolt Biotherapeutics positions in Q2 2023 and 4 closed out, a net change of 0 holders.
- The largest Bolt Biotherapeutics buyer in Q2 2023 was Tang Capital Management, an estimated $2.71M added.
- The largest Bolt Biotherapeutics seller in Q2 2023 was Morgan Stanley, an estimated $433K sold.
Based on aggregated 13F filings for Q2 2023.